Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2014 on request of the Sponsor.
On 15 April 2011, orphan designation (EU/3/11/853) was granted by the European Commission to Sanofi-Aventis, France, for ombrabulin for the treatment of soft tissue sarcoma.
In October 2012, Sanofi Aventis changed name to Sanofi-Aventis Groupe.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
|Disease / condition||
Treatment of soft tissue sarcoma
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.